Biogen Idec’s Reports Of Tysabri Side Effects Don’t Rattle FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Wall Street reacted sharply to disclosure of two new PML cases associated with Tysabri, but it doesn’t sound like FDA plans a regulatory response.
You may also be interested in...
FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use
FDA appears to be setting new policy on when drugs should be available for compassionate use
FDA Action On Off-Label Tysabri May Signal Policy Shift On Compassionate Use
FDA appears to be setting new policy on when drugs should be available for compassionate use
FDA Still Behind Tysabri Monotherapy
Medwatch warning is less strident than some feared.